News Join our mailing list to receive our quarterly email newsletter with news, updates and events in bowel management. SUBSCRIBE AllCancerCoeliac DiseaseConstipationIncontinenceIBSInflammatory Bowel DiseasePaediatricsBIG supports the Bladder and Bowel campaign 2021June 22, 2021NETTER-1 study for patients with midgut NETsJune 15, 2021Efficacy data for ustekinumab in Crohn’s disease & ulcerative colitis releasedMay 24, 2021NICE approve treatment for untreated metastatic colorectal cancerMay 14, 2021KEYTRUDA approved for gastric or gastroesophageal junction adenocarcinomaMay 6, 2021New digital platform for colorectal patients launched by Chelsea and Westminster HospitalApril 29, 2021Lilly reports positive data from its ulcerative colitis phase 3 trialApril 12, 2021Pembrolizumab added to NHSE COVID interim treatment list for colorectal cancerApril 6, 2021NICE recommends andexanet alfa (ONDEXXYA®▼) for uncontrolled bleeds in the gastrointestinal tractApril 6, 2021GSK presents positive efficacy data of dostarlimab in mismatch repair-deficient (dMMR) solid cancersJanuary 18, 2021New data show positive association between Remsima® SC pre-dose level with efficacy outcomesOctober 14, 2020Interim Results Released from Phase 2 Study on TREMFYA®▼ (guselkumab) in Patients with Crohn’s DiseaseOctober 14, 20204 123456789 5
New digital platform for colorectal patients launched by Chelsea and Westminster HospitalApril 29, 2021
NICE recommends andexanet alfa (ONDEXXYA®▼) for uncontrolled bleeds in the gastrointestinal tractApril 6, 2021
GSK presents positive efficacy data of dostarlimab in mismatch repair-deficient (dMMR) solid cancersJanuary 18, 2021
New data show positive association between Remsima® SC pre-dose level with efficacy outcomesOctober 14, 2020
Interim Results Released from Phase 2 Study on TREMFYA®▼ (guselkumab) in Patients with Crohn’s DiseaseOctober 14, 2020
